Skip to main content
Premium Trial:

Request an Annual Quote

Moderna Reports Efficacy Among Adolescents

Moderna's SARS-CoV-2 vaccine is effective among adolescents, NPR reports.

The company announced that its mRNA-based vaccine had an efficacy of 93 percent in preventing COVID-19 among 12- to 17-year-olds. Its trial included 3,732 adolescents, two-thirds of whom received the vaccine and one-third of whom received a placebo. Four cases of COVID-19 occurred in the placebo group and none in the vaccine group using the same disease criteria the company used for its adult trial and when a more stringent definition that encompasses milder disease, the vaccine had a 93 percent efficacy.

According to NPR, Moderna CEO Stéphane Bancel says the company plans to submit its results to the US Food and Drug Administration and other regulators next month. The Verge notes that the Moderna vaccine is currently authorized for people over the age of 18.

Pfizer and BioNTech similarly reported in late March that their vaccine was effective in preventing COVID-19 among adolescents and the FDA granted them Emergency Use Authorization for that age group earlier this month.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.